Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor symptoms such as depression, anxiety, and cognitive impairment, which significantly affect patients' quality of life. Traditional dopaminergic therapies address motor symptoms but offer limited efficacy for neuropsychia...
Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Level 1 Autism Spectrum Disorder), particularly those in underserved or marginalized communities. Emerging evidence suggests that psychedelic-assisted therapies-including psilocybin, MDMA, and ketamine-offer promising...
ABSTRACT Joshua Falcon's comprehensive synthesis, “Anthropology of Psychedelics,” significantly addresses gaps in psychedelic anthropology, particularly urban practices in the Global North and decolonial considerations. This commentary expands upon Falcon's work by incorporating recent clinical studies and sociocultural analyses that reinforce his proposed d...
Psychedelic drugs, known for their potent psychoactive effects, have gained attention for their potential therapeutic benefits in treating mental disorders.However, distressing experiences induced by psychedelics can lead to adverse long-term effects. To better assess these experiences, we aimed to provide a Norwegian translation and psychometric validation ...
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-sectional study evaluates the regulatory alignment of 40 clinical trials listed on ClinicalTrials.gov, focusing on the methodological challenges. The study highlights methodological inconsistencies, particularly a...
In a thought-provoking Genomic Press interview, Dr. Michael Wheeler emerges as a brilliant scientific innovator at the intersection of neuroscience and immunology. As an Assistant Professor at Harvard Medical School and an investigator at Brigham and Women's Hospital, Wheeler's groundbreaking research explores how brain-immune communication shapes our behavi...
Abstract Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant trials, approximately one-third of MDD patients remain symptomatic, progressing to treatment-resistant depression (TRD). This persistence possibly is due to the multifaceted etiology of TRD, encompassing bio...
Research into psychedelics' clinical potential has corresponded to a growth in public interest and adult use. One common pathway to accessing psychedelics is through psychedelic retreats. While individual retreats have been characterized in the anthropological literature, no systematic evaluation of the psychedelic retreat industry exists. Assessing the char...
Most Delphi studies primarily rely on questionnaires and subsequent quantitative ratings across multiple rounds to learn about a complex issue. This article demonstrates the integration of qualitative inquiry into a Delphi study to enhance and complement quantitative findings. We conducted a mixed methods Delphi study to establish a comprehensive list of qua...
Abstract PcncAAAD is a calcium-activatable noncanonical aromatic L-amino acid decarboxylase (AAAD) featuring a unique appendage C-terminal domain (CTD) and two metal-binding sites. In this study, we establish an in silico RMSD-based evaluation model through molecular dynamics simulations, validated by in vitro enzyme assays, to decipher the enzyme’s calcium ...
Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin's pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in con...
Psychiatric disorders are marked by habitual patterns of thought, emotion, and behavior, and many mental health disorders are resistant to standard treatments (1)(2)(3)(4). For example, symptoms of major depressive disorder include ruminative negative thoughts, pervasive sadness, and lack of goaldirected behavior (5)(6)(7). Similarly, many anxiety and trauma...
Abstract Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticit...
ObjectivesMood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been limited pharmacological advances in recent years, and available psychological interventions vary in degree of impact and durability as a treatment modality in this population. A recent renaissance in psy...
Background: Psilocybin has shown promise in therapeutic applications for mental disorders. Understanding the pharmacokinetics of psilocybin and its active metabolite psilocin is crucial for optimizing its clinical use and minimizing adverse effects. Methods: This systematic review involved a comprehensive search across MEDLINE, APA PsycINFO, and Embase datab...
Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initial studies suggest that psychedelics may be feasible for targeting pain, however clinical and preclinical controlled studies are necessary to further investigate that possibility. In this study we assessed the eff...
In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes studies on compounds such as psilocybin, MDMA, DMT, and LSD used for the treatment of depression, post-traum...
The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in recent decades due to their low toxicity and potential applications in treating various mental health disorders. However, producing pharmaceutical-grade psilocybin remains challenging, with three primary approaches:...
Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic seizures. Psilocin, the active metabolite of psilocybin, a well-known psychedelic compound, has recently gained attention for its potential antidepressant and anxiolytic properties. This study aims to investigate the anti...
